Cyproheptadine displays preclinical activity in myeloma and leukemia

Xinliang Mao, Sheng Ben Liang, Rose Hurren, Marcela Gronda, Sue Chow, G. Wei Xu, Xiaoming Wang, Reza Beheshti Zavareh, Nazir Jamal, Hans Messner, David W. Hedley, Alessandro Datti, Jeff L. Wrana, Yuanxiao Zhu, Chang Xin Shi, Kyle Lee, Rodger Tiedemann, Suzanne Trudel, Alexander Keith Stewart, Aaron D. Schimmer

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

D-cyclins are regulators of cell division that act in a complex with cyclindependent kinases to commit cells to a program of DNA replication. D-cyclins are overexpressed in many tumors, including multiple myeloma and leukemia, and contribute to disease progression and chemoresistance. To better understand the role and impact of D-cyclins in hematologic malignancies, we conducted a high throughput screen for inhibitors of the cyclin D2 promoter and identified the drug cyproheptadine. In myeloma and leukemia cells, cyproheptadine decreased expression of cyclins D1, D2, and D3 and arrested these cells in the G 0/G 1 phase. After D-cyclin suppression, cyproheptadine induced apoptosis in myeloma and leukemia cell lines and primary patient samples preferentially over normal hematopoietic cells. In mouse models of myeloma and leukemia, cyproheptadine inhibited tumor growth without significant toxicity. Cyproheptadine-induced apoptosis was preceded by activation of the mitochondrial pathway of caspase activation and was independent of the drug's known activity as an H1 histamine and serotonin receptor antagonist. Thus, cyproheptadine represents a lead for a novel therapeutic agent for the treatment of malignancy. Because the drug is well tolerated and already approved in multiple countries for clinical use as an antihistamine and appetite stimulant, it could be moved directly into clinical trials for cancer.

Original languageEnglish (US)
Pages (from-to)760-769
Number of pages10
JournalBlood
Volume112
Issue number3
DOIs
StatePublished - Aug 1 2008

Fingerprint

Cyproheptadine
Cyclin D
Leukemia
Cyclin D2
Tumors
Neoplasms
Appetite Stimulants
Chemical activation
Cells
Cyclin D3
Pharmaceutical Preparations
Apoptosis
Histamine Receptors
Histamine H1 Receptors
Gastrin-Secreting Cells
Serotonin Antagonists
Histamine Antagonists
Cyclin D1
Hematologic Neoplasms
Caspases

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Mao, X., Liang, S. B., Hurren, R., Gronda, M., Chow, S., Wei Xu, G., ... Schimmer, A. D. (2008). Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood, 112(3), 760-769. https://doi.org/10.1182/blood-2008-02-142687

Cyproheptadine displays preclinical activity in myeloma and leukemia. / Mao, Xinliang; Liang, Sheng Ben; Hurren, Rose; Gronda, Marcela; Chow, Sue; Wei Xu, G.; Wang, Xiaoming; Zavareh, Reza Beheshti; Jamal, Nazir; Messner, Hans; Hedley, David W.; Datti, Alessandro; Wrana, Jeff L.; Zhu, Yuanxiao; Shi, Chang Xin; Lee, Kyle; Tiedemann, Rodger; Trudel, Suzanne; Stewart, Alexander Keith; Schimmer, Aaron D.

In: Blood, Vol. 112, No. 3, 01.08.2008, p. 760-769.

Research output: Contribution to journalArticle

Mao, X, Liang, SB, Hurren, R, Gronda, M, Chow, S, Wei Xu, G, Wang, X, Zavareh, RB, Jamal, N, Messner, H, Hedley, DW, Datti, A, Wrana, JL, Zhu, Y, Shi, CX, Lee, K, Tiedemann, R, Trudel, S, Stewart, AK & Schimmer, AD 2008, 'Cyproheptadine displays preclinical activity in myeloma and leukemia', Blood, vol. 112, no. 3, pp. 760-769. https://doi.org/10.1182/blood-2008-02-142687
Mao X, Liang SB, Hurren R, Gronda M, Chow S, Wei Xu G et al. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008 Aug 1;112(3):760-769. https://doi.org/10.1182/blood-2008-02-142687
Mao, Xinliang ; Liang, Sheng Ben ; Hurren, Rose ; Gronda, Marcela ; Chow, Sue ; Wei Xu, G. ; Wang, Xiaoming ; Zavareh, Reza Beheshti ; Jamal, Nazir ; Messner, Hans ; Hedley, David W. ; Datti, Alessandro ; Wrana, Jeff L. ; Zhu, Yuanxiao ; Shi, Chang Xin ; Lee, Kyle ; Tiedemann, Rodger ; Trudel, Suzanne ; Stewart, Alexander Keith ; Schimmer, Aaron D. / Cyproheptadine displays preclinical activity in myeloma and leukemia. In: Blood. 2008 ; Vol. 112, No. 3. pp. 760-769.
@article{5297e9de14a8468bb20528e50769f7c4,
title = "Cyproheptadine displays preclinical activity in myeloma and leukemia",
abstract = "D-cyclins are regulators of cell division that act in a complex with cyclindependent kinases to commit cells to a program of DNA replication. D-cyclins are overexpressed in many tumors, including multiple myeloma and leukemia, and contribute to disease progression and chemoresistance. To better understand the role and impact of D-cyclins in hematologic malignancies, we conducted a high throughput screen for inhibitors of the cyclin D2 promoter and identified the drug cyproheptadine. In myeloma and leukemia cells, cyproheptadine decreased expression of cyclins D1, D2, and D3 and arrested these cells in the G 0/G 1 phase. After D-cyclin suppression, cyproheptadine induced apoptosis in myeloma and leukemia cell lines and primary patient samples preferentially over normal hematopoietic cells. In mouse models of myeloma and leukemia, cyproheptadine inhibited tumor growth without significant toxicity. Cyproheptadine-induced apoptosis was preceded by activation of the mitochondrial pathway of caspase activation and was independent of the drug's known activity as an H1 histamine and serotonin receptor antagonist. Thus, cyproheptadine represents a lead for a novel therapeutic agent for the treatment of malignancy. Because the drug is well tolerated and already approved in multiple countries for clinical use as an antihistamine and appetite stimulant, it could be moved directly into clinical trials for cancer.",
author = "Xinliang Mao and Liang, {Sheng Ben} and Rose Hurren and Marcela Gronda and Sue Chow and {Wei Xu}, G. and Xiaoming Wang and Zavareh, {Reza Beheshti} and Nazir Jamal and Hans Messner and Hedley, {David W.} and Alessandro Datti and Wrana, {Jeff L.} and Yuanxiao Zhu and Shi, {Chang Xin} and Kyle Lee and Rodger Tiedemann and Suzanne Trudel and Stewart, {Alexander Keith} and Schimmer, {Aaron D.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1182/blood-2008-02-142687",
language = "English (US)",
volume = "112",
pages = "760--769",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Cyproheptadine displays preclinical activity in myeloma and leukemia

AU - Mao, Xinliang

AU - Liang, Sheng Ben

AU - Hurren, Rose

AU - Gronda, Marcela

AU - Chow, Sue

AU - Wei Xu, G.

AU - Wang, Xiaoming

AU - Zavareh, Reza Beheshti

AU - Jamal, Nazir

AU - Messner, Hans

AU - Hedley, David W.

AU - Datti, Alessandro

AU - Wrana, Jeff L.

AU - Zhu, Yuanxiao

AU - Shi, Chang Xin

AU - Lee, Kyle

AU - Tiedemann, Rodger

AU - Trudel, Suzanne

AU - Stewart, Alexander Keith

AU - Schimmer, Aaron D.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - D-cyclins are regulators of cell division that act in a complex with cyclindependent kinases to commit cells to a program of DNA replication. D-cyclins are overexpressed in many tumors, including multiple myeloma and leukemia, and contribute to disease progression and chemoresistance. To better understand the role and impact of D-cyclins in hematologic malignancies, we conducted a high throughput screen for inhibitors of the cyclin D2 promoter and identified the drug cyproheptadine. In myeloma and leukemia cells, cyproheptadine decreased expression of cyclins D1, D2, and D3 and arrested these cells in the G 0/G 1 phase. After D-cyclin suppression, cyproheptadine induced apoptosis in myeloma and leukemia cell lines and primary patient samples preferentially over normal hematopoietic cells. In mouse models of myeloma and leukemia, cyproheptadine inhibited tumor growth without significant toxicity. Cyproheptadine-induced apoptosis was preceded by activation of the mitochondrial pathway of caspase activation and was independent of the drug's known activity as an H1 histamine and serotonin receptor antagonist. Thus, cyproheptadine represents a lead for a novel therapeutic agent for the treatment of malignancy. Because the drug is well tolerated and already approved in multiple countries for clinical use as an antihistamine and appetite stimulant, it could be moved directly into clinical trials for cancer.

AB - D-cyclins are regulators of cell division that act in a complex with cyclindependent kinases to commit cells to a program of DNA replication. D-cyclins are overexpressed in many tumors, including multiple myeloma and leukemia, and contribute to disease progression and chemoresistance. To better understand the role and impact of D-cyclins in hematologic malignancies, we conducted a high throughput screen for inhibitors of the cyclin D2 promoter and identified the drug cyproheptadine. In myeloma and leukemia cells, cyproheptadine decreased expression of cyclins D1, D2, and D3 and arrested these cells in the G 0/G 1 phase. After D-cyclin suppression, cyproheptadine induced apoptosis in myeloma and leukemia cell lines and primary patient samples preferentially over normal hematopoietic cells. In mouse models of myeloma and leukemia, cyproheptadine inhibited tumor growth without significant toxicity. Cyproheptadine-induced apoptosis was preceded by activation of the mitochondrial pathway of caspase activation and was independent of the drug's known activity as an H1 histamine and serotonin receptor antagonist. Thus, cyproheptadine represents a lead for a novel therapeutic agent for the treatment of malignancy. Because the drug is well tolerated and already approved in multiple countries for clinical use as an antihistamine and appetite stimulant, it could be moved directly into clinical trials for cancer.

UR - http://www.scopus.com/inward/record.url?scp=50949098862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50949098862&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-02-142687

DO - 10.1182/blood-2008-02-142687

M3 - Article

C2 - 18502826

AN - SCOPUS:50949098862

VL - 112

SP - 760

EP - 769

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -